Accreditation: 6.00 Nursing Contact Hours | 6.00 AMA PRA Category 1 Credit™ | 6.00 ABIM MOC II | 6.00 ACPE Pharmacy
Venue: Westgate Resorts, 3000 Canyons Resort Drive, Park City, UT, United States
Official conference page for 2025 Park City Myeloma & Lymphoma Summit. https://binaytara.org/projects/conferences/2025-park-city-myeloma-lymphoma-summit
Saturday, October 11th, 2025
All timings are in Mountain Time (MDT, GMT-06:00) time.
08:15 AM - 08:25 AM
Introductions – Douglas W Sborov, MD
08:25 AM - 08:45 AM
CAR-T in Perspective: Role of CAR-T in the RRMM Setting – Lekha Mikkilineni, MD
08:45 AM - 09:05 AM
Bispecific T-cell Engagers: Standard of care, Combination Regimens, and the Future – Amandeep Godara, MBBS
09:05 AM - 09:25 AM
Drug Sequencing: The Value of Real-World Data – Doris Hansen, MD
09:25 AM - 09:35 AM
Data in Perspective: Where We Are and Where We Are Going – Lekha Mikkilineni, MD
09:35 AM - 09:55 AM
Panel Q&A/Debate – Lekha Mikkilineni, MD; Amandeep Godara, MBBS; Doris Hansen, MD; Douglas W Sborov, MD
10:10 AM - 10:40 AM
Standard of Care and Unmet Needs in First-Line Treatment in 2025 – Andrew Yee, MD
10:40 AM - 11:05 AM
Transplant and Maintenance in the Modern Era – Craig Hofmeister, MD, MPH
11:05 AM - 11:15 AM
Data in Perspective: Future of Upfront Treatment for NDMM – Amandeep Godara, MBBS
11:15 AM - 11:30 AM
Panel Q&A/Debate – Andrew Yee, MD; Craig Hofmeister, MD, MPH; Amandeep Godara, MBBS; Douglas W Sborov, MD
11:30 AM - 11:40 AM
"Down with Dex" in Myeloma Therapy – Benjamin Solomon, MD
11:40 AM - 11:50 AM
Successful Implementation of a Community-Based Bispecific Program – Wayne Ormsby, MD
11:50 AM - 12:05 PM
Mitigation Strategies for CAR-T and Bispecific-Associated Toxicities – Samuel Shewan, PA-C
12:05 PM - 12:20 PM
Panel Q&A/Debate – Benjamin Solomon, MD; Wayne Ormsby, MD; Samuel Shewan, PA-C; Xylina Gregg, MD
Session Chair: Bradley Hunter, MD
01:20 PM - 01:40 PM
DLBCL in 2025 - Role of MRD in response assessment and surveillance, new treatment options for r/r DLBCL (transplant-ineligible options + CAR T/BsAbs), role of CNS prophylaxis – Richard T. Maziarz, MD
01:40 PM - 01:50 PM
Debate 1: Is there still a role for CNS prophylaxis in DLBCL? – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD
01:50 PM - 02:00 PM
Debate 2: Best 2L + option for transplant ineligible LBCL patients — bispecific + GemOx (STARGLO, EPCORE NHL-2) vs. Mosun+Pola (SUNMO trial) – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD
02:00 PM - 02:10 PM
What's in the Pipeline? New Drugs on the Horizon for Lymphoma – Justin Call, MD
02:10 PM - 02:20 PM
Data in Perspective: DLBCL – Belisario Arango, MD
02:20 PM - 02:35 PM
Q&A – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD; Justin Call, MD; Belisario Arango, MD; Bradley Hunter, MD
Session Chair: Lindsey Fitzgerald, MD, PhD
02:55 PM - 03:20 PM
CLL in 2025 - touching on MRD, doublet/triplet regimens – Stephen Spurgeon, MD
03:20 PM - 03:30 PM
Debate 1: Is fixed-duration doublet or triplet therapy the future for untreated CLL? (Acalabrutinib, venetoclax +/- obinutuzumab - AMPLIFY; Sonrotoclax + Zanubrutinib - MAJIC, etc) – Matthew Mei, MD; Victoria Vardell, MD
03:30 PM - 03:40 PM
Debate 2: What is the best treatment for TP53-mutated CLL - BTKi or venetoclax-based? – Daniel Arthur Ermann, MD; Matthew Mei, MD
03:40 PM - 03:55 PM
Q&A – Stephen Spurgeon, MD; Matthew Mei, MD; Daniel Arthur Ermann, MD; Victoria Vardell, MD; Lindsey Fitzgerald, MD, PhD
This activity is supported with an Independent Medical Education grant from Legend Biotech
